Literature DB >> 26188759

Molecularly targeted radiosensitization chances towards gene aberration-due organ confined/regionally advanced prostate cancer radioresistance.

C Alberti.   

Abstract

Considering that the prostate cancer radioresistance occurs in a significant percentage--as 20-40% of prostate cancer (PCa) patients undergone external beam radiation therapy developing, within ten years, recurrent and more aggressive tumor--the resort to customized radiosensitizer measures, focusly targeting PCa radioresistance-linked individual molecular aberrations, can increase the successful outcomes of PCa radiotherapy.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26188759      PMCID： PMC4511043          DOI： 10.11138/gchir/2015.36.3.133

Source DB:  PubMed          Journal:  G Chir        ISSN： 0391-9005


  18 in total

Review 1.  Alternative Splicing, DNA Damage and Modulating Drugs in Radiation Therapy for Cancer.

Authors:  Jen-Yang Tang; Ruei-Nian Li; Ping-Ho Chen; Hurng-Wern Huang; Ming-Feng Hou; Hsueh-Wei Chang
Journal:  Anticancer Agents Med Chem       Date:  2015       Impact factor: 2.505

2.  Pre-radiotherapy identification of individual genomic profile to avoid, by resort to customized radiosensitizers, the risk of radioresistance development in patients with localized prostate cancer.

Authors:  C Alberti
Journal:  Br J Radiol       Date:  2015-01       Impact factor: 3.039

3.  Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models.

Authors:  Giovanni Luca Gravina; Francesco Marampon; David Sherris; Francesca Vittorini; Ernesto Di Cesare; Vincenzo Tombolini; Andrea Lenzi; Emmanuele A Jannini; Claudio Festuccia
Journal:  Prostate       Date:  2014-04-08       Impact factor: 4.104

4.  Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.

Authors:  C Alberti
Journal:  G Chir       Date:  2010 Nov-Dec

5.  Targeting CREB inhibits radiation-induced neuroendocrine differentiation and increases radiation-induced cell death in prostate cancer cells.

Authors:  Christopher D Suarez; Xuehong Deng; Chang-Deng Hu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

Review 6.  Prostate cancer: radioresistance molecular target-related markers and foreseeable modalities of radiosensitization.

Authors:  C Alberti
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014-08       Impact factor: 3.507

7.  Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.

Authors:  Roque Diaz; Paul A Nguewa; Miriam Redrado; Irene Manrique; Alfonso Calvo
Journal:  Prostate       Date:  2015-04-20       Impact factor: 4.104

8.  A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation.

Authors:  Koji Hatano; Binod Kumar; Yonggang Zhang; Jonathan B Coulter; Mohammad Hedayati; Brian Mears; Xiaohua Ni; Tarana A Kudrolli; Wasim H Chowdhury; Ronald Rodriguez; Theodore L DeWeese; Shawn E Lupold
Journal:  Nucleic Acids Res       Date:  2015-04-06       Impact factor: 16.971

9.  Imaging of HER2 may improve the outcome of external irradiation therapy for prostate cancer patients.

Authors:  Jennie Andersson; Maria Rosestedt; Anna Orlova
Journal:  Oncol Lett       Date:  2014-12-03       Impact factor: 2.967

10.  Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.

Authors:  Robert B Den; Felix Y Feng; Timothy N Showalter; Mark V Mishra; Edouard J Trabulsi; Costas D Lallas; Leonard G Gomella; W Kevin Kelly; Ruth C Birbe; Peter A McCue; Mercedeh Ghadessi; Kasra Yousefi; Elai Davicioni; Karen E Knudsen; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038
View more
  1 in total

Review 1.  Highlighting the Potential for Chronic Stress to Minimize Therapeutic Responses to Radiotherapy through Increased Immunosuppression and Radiation Resistance.

Authors:  Minhui Chen; Anurag K Singh; Elizabeth A Repasky
Journal:  Cancers (Basel)       Date:  2020-12-20       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.